MSFT   183.29 (-0.12%)
FB   236.83 (+0.82%)
GOOGL   1,437.48 (+1.72%)
NVDA   352.77 (-2.29%)
CGC   20.55 (+5.71%)
BABA   204.06 (+2.18%)
MU   46.02 (+2.40%)
TSLA   821.36 (+0.55%)
AMD   54.48 (-1.25%)
F   5.87 (+3.90%)
GILD   74.07 (+1.00%)
NFLX   416.58 (-2.97%)
BA   144.36 (+4.97%)
MSFT   183.29 (-0.12%)
FB   236.83 (+0.82%)
GOOGL   1,437.48 (+1.72%)
NVDA   352.77 (-2.29%)
CGC   20.55 (+5.71%)
BABA   204.06 (+2.18%)
MU   46.02 (+2.40%)
TSLA   821.36 (+0.55%)
AMD   54.48 (-1.25%)
F   5.87 (+3.90%)
GILD   74.07 (+1.00%)
NFLX   416.58 (-2.97%)
BA   144.36 (+4.97%)
MSFT   183.29 (-0.12%)
FB   236.83 (+0.82%)
GOOGL   1,437.48 (+1.72%)
NVDA   352.77 (-2.29%)
CGC   20.55 (+5.71%)
BABA   204.06 (+2.18%)
MU   46.02 (+2.40%)
TSLA   821.36 (+0.55%)
AMD   54.48 (-1.25%)
F   5.87 (+3.90%)
GILD   74.07 (+1.00%)
NFLX   416.58 (-2.97%)
BA   144.36 (+4.97%)
MSFT   183.29 (-0.12%)
FB   236.83 (+0.82%)
GOOGL   1,437.48 (+1.72%)
NVDA   352.77 (-2.29%)
CGC   20.55 (+5.71%)
BABA   204.06 (+2.18%)
MU   46.02 (+2.40%)
TSLA   821.36 (+0.55%)
AMD   54.48 (-1.25%)
F   5.87 (+3.90%)
GILD   74.07 (+1.00%)
NFLX   416.58 (-2.97%)
BA   144.36 (+4.97%)
Log in

NASDAQ:RCMR1 RCM Stock Price, Forecast & News

$10.40
-0.15 (-1.42 %)
(As of 05/26/2020 12:51 PM ET)
Add
Compare
Today's Range
$10.31
Now: $10.40
$10.64
50-Day Range
$8.06
MA: $9.61
$10.37
52-Week Range
$7.12
Now: $10.40
$13.99
Volume29,075 shs
Average Volume1.00 million shs
Market Capitalization$1.19 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.52
R1 RCM Inc. provides revenue cycle management (RCM) for healthcare providers in the United States. It offers end-to-end RCM services to manage their revenue cycle operations, which encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, and bill preparation and collection from patients and payers. The company also provides modular services comprising physician advisory services, which assists hospitals in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes; practice management services that offers administrative and operational support for patient care and outsource non-core functions; and revenue capture services, including charge capture, charge description master maintenance, and pricing services. It serves healthcare providers, including health systems and hospitals, physicians groups, and municipal and private emergency medical service providers, as well as intermountain homecare, hospice and palliative care, and durable medical equipment and infusion therapy business. The company was formerly known as Accretive Health, Inc. and changed its name to R1 RCM Inc. in January 2017. R1 RCM Inc. was founded in 2003 and is headquartered in Chicago, Illinois.
Read More
R1 RCM logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.46 out of 5 stars


Industry, Sector and Symbol

Industry Management services
Sub-IndustryHealth Care Services
SectorFinance
Current SymbolNASDAQ:RCM
CUSIP00438V10
Phone312-324-7820

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.19 billion
Cash Flow$0.62 per share
Book Value$0.16 per share

Profitability

Net Income$12 million

Miscellaneous

Employees22,500
Market Cap$1.19 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive RCM News and Ratings via Email

Sign-up to receive the latest news and ratings for RCM and its competitors with MarketBeat's FREE daily newsletter.

R1 RCM (NASDAQ:RCM) Frequently Asked Questions

How has R1 RCM's stock been impacted by COVID-19 (Coronavirus)?

R1 RCM's stock was trading at $10.16 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, RCM stock has increased by 2.4% and is now trading at $10.40. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of R1 RCM?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for R1 RCM in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for R1 RCM.

When is R1 RCM's next earnings date?

R1 RCM is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for R1 RCM.

How were R1 RCM's earnings last quarter?

R1 RCM Inc (NASDAQ:RCM) posted its earnings results on Tuesday, May, 5th. The healthcare provider reported $0.05 EPS for the quarter, missing the Zacks' consensus estimate of $0.08 by $0.03. The healthcare provider earned $320.50 million during the quarter, compared to analysts' expectations of $318.76 million. R1 RCM had a return on equity of 174.42% and a net margin of 2.44%. The firm's quarterly revenue was up 16.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.04) EPS. View R1 RCM's earnings history.

What price target have analysts set for RCM?

6 equities research analysts have issued 1 year target prices for R1 RCM's stock. Their forecasts range from $10.00 to $17.00. On average, they anticipate R1 RCM's stock price to reach $13.83 in the next twelve months. This suggests a possible upside of 33.0% from the stock's current price. View analysts' price targets for R1 RCM.

Has R1 RCM been receiving favorable news coverage?

News headlines about RCM stock have trended extremely negative recently, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. R1 RCM earned a media sentiment score of -5.0 on InfoTrie's scale. They also gave media headlines about the healthcare provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutR1 RCM.

Are investors shorting R1 RCM?

R1 RCM saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 4,660,000 shares, a decrease of 6.6% from the April 30th total of 4,990,000 shares. Based on an average trading volume of 1,220,000 shares, the days-to-cover ratio is presently 3.8 days. Currently, 4.3% of the shares of the stock are short sold. View R1 RCM's Current Options Chain.

Who are some of R1 RCM's key competitors?

What other stocks do shareholders of R1 RCM own?

Based on aggregate information from My MarketBeat watchlists, some companies that other R1 RCM investors own include NVIDIA (NVDA), Alibaba Group (BABA), JD.Com (JD), Baozun (BZUN), Marvell Technology Group (MRVL), Model N (MODN), Baidu (BIDU), BioDelivery Sciences International (BDSI), Perficient (PRFT) and RingCentral (RNG).

Who are R1 RCM's key executives?

R1 RCM's management team includes the following people:
  • Mr. Joseph Gerard Flanagan, Pres, CEO & Director (Age 48)
  • Mr. Gary S. Long, Exec. VP & Chief Commercial Officer (Age 49)
  • Mr. Richard B. Evans Jr., Sr. VP, Interim CFO, Corp. Controller & Chief Accounting Officer (Age 51)
  • Mr. Atif A. Rahim, Sr. VP of Investor Relations & Bus. Devel.
  • Mr. Corey Perman, Exec. VP of Compliance & Risk

What is R1 RCM's stock symbol?

R1 RCM trades on the NASDAQ under the ticker symbol "RCM."

Who are R1 RCM's major shareholders?

R1 RCM's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.71%), Wellington Management Group LLP (4.63%), Paradigm Capital Management Inc. NY (3.97%), Sunriver Management LLC (2.91%), State Street Corp (1.98%) and Bank of New York Mellon Corp (1.81%). Company insiders that own R1 RCM stock include Albert Rene Zimmerli, Charles J Ditkoff and Joseph Gerard Flanagan. View institutional ownership trends for R1 RCM.

Which institutional investors are selling R1 RCM stock?

RCM stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Two Sigma Investments LP, Russell Investments Group Ltd., Wellington Management Group LLP, Deutsche Bank AG, Invesco Ltd., BlackRock Inc., and Parametric Portfolio Associates LLC. View insider buying and selling activity for R1 RCM.

Which institutional investors are buying R1 RCM stock?

RCM stock was bought by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, Sunriver Management LLC, Nuveen Asset Management LLC, Monarch Partners Asset Management LLC, Two Sigma Advisers LP, Rice Hall James & Associates LLC, Penn Capital Management Co. Inc., and Geode Capital Management LLC. Company insiders that have bought R1 RCM stock in the last two years include Albert Rene Zimmerli, and Joseph Gerard Flanagan. View insider buying and selling activity for R1 RCM.

How do I buy shares of R1 RCM?

Shares of RCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is R1 RCM's stock price today?

One share of RCM stock can currently be purchased for approximately $10.40.

How big of a company is R1 RCM?

R1 RCM has a market capitalization of $1.19 billion and generates $1.19 billion in revenue each year. The healthcare provider earns $12 million in net income (profit) each year or ($0.08) on an earnings per share basis. R1 RCM employs 22,500 workers across the globe.

What is R1 RCM's official website?

The official website for R1 RCM is www.r1rcm.com.

How can I contact R1 RCM?

R1 RCM's mailing address is 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611. The healthcare provider can be reached via phone at 312-324-7820 or via email at [email protected]

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.